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EzrinWe are here reporting that in peripheral blood mononuclear cells (PBMC) of patients homozygous for
F508del-CFTR the calpain–calpastatin system undergoes a profound alteration. In fact, calpain basal activity,
almost undetectable in control PBMC, becomes measurable at a signiﬁcant extent in cells from cystic ﬁbrosis
(CF) patients, also due to a 40–60% decrease in both calpastatin protein and inhibitory activity. Constitutive
protease activation in CF patients' cells induces a large accumulation of the mutated cystic ﬁbrosis transmem-
brane conductance regulator (CFTR) in the 100 kD+70 kD split forms as well as a degradation of proteins as-
sociated to the CFTR complex. Speciﬁcally, the scaffolding protein Na+/H+ exchanger 3 regulatory factor-1
(NHERF-1) is converted in two distinct fragments showing masses of 35 kD and 20 kD, being however the
latter form the most represented one, thereby indicating that in CF-PBMC the CFTR complex undergoes a
large disorganization. In conclusion, our observations are providing new information on the role of calpain
in the regulation of plasma membrane ion conductance and provide additional evidence on the transition
of this protease activity from a physiological to a pathological function.s transmembrane conductance
PBMC, peripheral blood mono-
+39 010 518343.
rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
It is clearly emerging that transduction of biological signals is medi-
ated by the dynamic assembly of signalling complexes organized on the
inner surface of plasma membranes by transmembrane ion channels
[1,2]. A number of these complexes possess on its cytosolic region a
PDZ-binding motif which triggers the onset of these protein clusters
[3–5]. For instance, this association has been indicated in the case of
N-methyl-D-aspartate receptor (NMDAR) and cystic ﬁbrosis transmem-
brane conductance regulator (CFTR), being both involved in the forma-
tion of signalling complexes through their PDZ-binding motif [6–10].
These functional clusters are generated by the association to the PDZ-
binding structures of scaffolding proteins, such as PSD95 or EBP50,
that contain multiple PDZ domains. Thus the organization of the func-
tional complexes is further extended, with the inclusion of chaperones
and enzymes promoting selective signalling cascades. CFTR is assem-
bled in a functional multiprotein complex in which the scaffolding pro-
tein NHERF-1 exerts a central role in recruiting different cytoskeletalproteins, such as ezrin, and cAMP-dependent protein kinase (PKA)
required for the channel activation [11]. These channels and some
of their protein partners can be digested by calpain. Speciﬁcally, it
has been established that NMDAR subunits are cleaved by calpain
[12] and, more recently [13], we have demonstrated that mature
CFTR is cleaved by calpain in two discrete fragments having a mass of
100 kD and 70 kD respectively. These fragments remain associated
each other into the membrane moiety and are rapidly internalized in
endosomes. These sequential events may represent the initial step of
CFTR turnover, subsequently completed by lysosomal proteases. We
have also observed that F508del-CFTR is more susceptible to calpain
proteolysis due to a decreased afﬁnity for HSP90, resulting in a much
less efﬁcient protection by this chaperone [14]. In PBMC from CF pa-
tients (CF-PBMC), CFTR proteolysis is enhanced, suggesting an overacti-
vation of calpain that ﬁnally leads to the almost complete absence of
mature CFTR at plasma membrane [14,15].
We are now reporting that in CF-PBMC an unbalance in the calpain/
calpastatin system is responsible for overactivation of calpain which
in turn degrades NHERF-1 and ezrin modifying also their cellular distri-
bution. NHERF-1 digestion has been conﬁrmed both in reconstructed
systems and isolated cells.
Our observations provide additional evidence on the transition of
calpain from a physiological to a pathological role, a condition inducing
the uncontrolled digestion of these protein complexes.
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2.1. Materials
Leupeptin, calcium ionophore A23187 and C.I.1 (calpain inhibitor 1)
were purchased from Sigma-Aldrich. 4-(2-aminoethyl) benzene-
sulfonylﬂuoride (AEBSF) was obtained from Calbiochem. ECL
ADVANCE® Detection System was obtained from GE Healthcare. t-BOC
(t-butoxycarbonyl)-Leu-Met-CMAC (7-amino-4-chlorometylcoumarin),
a ﬂuorogenic calpain substrate was purchased from Molecular Probes
(Invitrogen). Ficoll-Pacque Plus was obtained from GE Healthcare.
Human erythrocyte calpain was isolated and assayed as reported in
[16]. One unit of calpain activity is deﬁned as the amount that releases
1 nMol/h of free a-amino groups under the speciﬁed conditions [17].
Anti-NHERF-1 (H-100) polyclonal antibody was purchased from
Santa Cruz biotechnology, inc. Anti-CFTR monoclonal antibody (clone
M3A7) was purchased from Millipore. Anti-CFTR polyclonal antibody
was purchased from Cell Signaling. Anti-ezrin monoclonal antibody
(18/Ezrin)was purchased fromBD Transduction LaboratoriesTM.Mono-
clonal anti-μ-calpain (calpain I, subunit p80) clone 15C10 was obtained
from Sigma-Aldrich. Calpastatin was detected with the monoclonal
antibody 35.23 [18].
2.2. Donor subjects and sample collection
12 CF patients homozygous for F508del-CFTR mutation, 3 obligates
heterozygotes (CF patient mothers) and 10 healthy donors were
enrolled in the study. CF patients (6 males; mean age: 28, range:
9÷55, mean FEV1% predicted value for height, sex and age 54%,
range: 20÷108; 12/12 with pancreatic insufﬁciency) were regularly
followed at the Cystic Fibrosis Center, Pediatric Department Institute G.
Gaslini, Genoa, Italy. For every patient and healthy donor, a sample of
6 ml of blood was collected in two 3 ml vacuette® PREMIUM tubes
containing 5 mM EDTA.
2.3. Assay of intracellular calpain activity
Calpain activity was detected in intact PBMC following the proce-
dure described in [19]. Brieﬂy, PBMC were collected, washed three
times in PBS solution, and incubated for 20 min at 37 °C in buffer A
(10 mM Hepes, pH 7.4, 0.14 M NaCl, 5 mM KCl, and 5 mM glucose)
containing 50 μM t-Boc-Leu-Met-CMAC, the ﬂuorogenic calpain sub-
strate. Cells were washed with buffer A to remove substrate excess.
The pellets were resuspended to give 106 cells/ml in buffer A contain-
ing 0.1 mM CaCl2. Aliquots (2×105 cells) were transferred to 96-well
plates and the ﬂuorescence emission was continuously monitored at
37 °C with a Mithras LB940 plate reader (Berthold Technologies) in the
absence or presence of 2 μM Ca2+-ionophore A23187. The excitation/
emission wavelengths were 355/485 nm respectively.
2.4. Separation and quantiﬁcation of calpastatin species in human PBMC,
following SDS-polyacrylamide gel electrophoresis
Crude extracts obtained from 4×106 PBMC from healthy donors
(C-PBMC) and CF-PBMC were submitted to SDS-polyacrilamide gel
electrophoresis (10%) divided in 10 lanes. Calpastatin species were
identiﬁed following protein extraction from the gel, as previously
described [20]. Calpastatin activity was measured as described [21].
2.5. Confocal microscopy imaging and ﬂuorescence quantiﬁcation
PBMC (10×106) isolated as previously described [22] from
control and CF patients were ﬁxed and permeabilized by the Triton/
paraformaldehyde method, as described in [23]. Cells were treated
with 10 μg/ml CFTR antibody (M3A7) or, alternatively, with 4 μg/ml
NHERF-1 antibody diluted in PBS solution, containing 5% (v/v) FBS.After incubation for 3 h at 25 °C, cells were washed three times with
PBS solution and treated with 4 μg/ml chicken anti-(mouse IgG) Alexa
ﬂuor® 488-conjugate secondary antibody (Molecular Probes) for 1 h.
Chromatin was stained by exposing ﬁxed and permeabilized cells to
2 μg/ml propidium iodide for 5 min [24]. Images were collected using
a Bio-RadMRC1024 confocalmicroscopy,with a 60× Plan Apo objective
with numerical aperture 1.4. The excitation/emission wavelengths for
propidium iodide-stained chromatin were 488–568/605 nm. Sequen-
tial acquisitions were performed to avoid cross-talk between colour
channels. The ﬂuorescence intensity in each image was quantiﬁed
using LaserPix software (Bio-Rad) following the procedure described
in [25].
2.6. Isolation of the membrane and solubilized fractions from PBMC
PBMC were washed three times with ice-cold PBS solution. The
cells (10×106) were lysed in 1 ml buffer A (50 mM sodium borate,
1 mM EDTA, pH 7.5), containing 5 mg leupeptin and 10 mg AEBSF,
by three cycles of freezing and thawing followed by sonication
(total material). The total particulate material was separated from
the supernatant by centrifugation at 100,000 g for 10 min at 4 °C
and washed three times in buffer A (total membrane fraction).
When indicated the membrane fractions were washed in ten volumes
(500 μl) of buffer A containing 0.5 M NaCl or 1 M NaCl and centri-
fuged at 100,000 g for 10 min. Supernatants (solubilized material)
and pellets (washed membranes) were separately collected. The pro-
tein concentration was determined following the method of Lowry.
2.7. Immunoprecipitation and immunoblotting
Total membrane fraction isolated from 10×106 PBMC, as described
earlier, was solubilized in 500 μl buffer A containing 0.15 MNaCl and 1%
Triton® X-100. Themixture, pre-treated with protein G-Sepharose, was
incubated with 2 μg of anti-CFTR antibody (clone M3A7) for 15 h at
4 °C. Protein G-Sepharose was then added to the sample which was in-
cubated for an additional 1 h with continuous and gentle shaking. The
immunocomplexes were washed three times with buffer A, incubated
at 95 °C in Laemmli loading buffer for 10 min and submitted to 12%
SDS-PAGE [26]. Proteins were then transferred to nitrocellulose mem-
branes (Bio-Rad) by electroblotting [27] and probed with the anti-
NHERF-1 antibody, followed by a peroxidase-conjugated secondary an-
tibody as described in [28]. Alternatively three different amounts (10,
20 and 30 μg) of total, membrane, soluble, solubilized, and washed
membranes fractions were submitted in triplicate to SDS-PAGE fol-
lowed by electroblotting. Membranes were then probed with the spe-
ciﬁc antibodies. The immunoreactive material was developed with
ECL ADVANCE® detection system, detected with a Bio-Rad Chemi Doc
XRS apparatus, and quantiﬁed using the Quantity One 4.6.1 software
(Bio-Rad Laboratories). The values of the arithmetical mean of the
three determinations were considered only if the amounts were on a
straight line.
3. Results
Wehave previously observed that calpain catalyzes the conservative
proteolysis of native CFTR [14] andwe have also established that in cells
expressing F508del-CFTR the split channel form is accumulated in
higher amounts as compared to controls [13]. To better characterize
such proteolytic events we have analyzed the level of calpain activity
in PBMC collected from controls and CF patients. These cells were se-
lected due to the fact that F508del-CFTR is almost absent from plasma
membrane, as observed in airway cells of CF patients, and that a defec-
tive immuno-response could be directly related to the severity of CF pa-
thology [29]. PBMC were loaded with a calpain ﬂuorogenic substrate
and ﬂuorescence intensity was continuously monitored for 20 min. In
control cells (Fig. 1A), no signiﬁcant changes in ﬂuorescence were
Fig. 1. Calpain and calpastatin system in PBMC fromcontrol and CFpatients. Aliquots corresponding to 2×105 PBMC from3 control (A) and 3 CF patients (B)were treated (as described in
Section 2.3) to measure intracellular calpain activity in the absence (ﬁlled circles) or presence of 2 μM Ca2+-ionophore (unﬁlled circles) or of 2 μM Ca2+-ionophore and 1 μM C.I.1 (ﬁlled
triangles). The values reported are the means±S.D. for three different experiments. (C) Calpastatin activity was measured as reported in Section 2.4. Calpain activity has been assayed,
following chromatographic separation of the protease from calpastatin, as previously described [19]. Aliquots corresponding to 2×105 PBMC from control (C) and CF patients (CF) were
solubilized in Laemmli SDS/PAGE loading solution and submitted to 10% SDS/PAGE followed by immunoblotting. Calpain and calpastatin were detected using the speciﬁc antibodies and
the protein bands were quantiﬁed as described in Section 2.7. The values of protein and activity quantiﬁcation are reported as the means±S.D. for three different experiments.
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able following exposure of C-PBMC to 2 μM Ca2+-ionophore A23187.
On the contrary, in cells from CF patients (Fig. 1B), the initial ﬂuores-
cence intensity was higher than in controls and it progressively in-
creased during the time of incubation. Following loading CF-PBMC
with calcium in the presence of 2 μMCa2+-ionophore A23187 a further
increase in the hydrolysis of the ﬂuorogenic substrate was detected.
In CF cells, preloaded with the synthetic calpain inhibitor-1 (C.I.1),
the higher basal ﬂuorescence and its progressive increase during the
incubation time were both abolished, indicating that the two events
are due to a calpain-mediated hydrolysis of the ﬂuorogenic substrate.
Comparing the rate of the ﬂuorogenic substrate hydrolysis in
untreated or Ca2+-enriched control and CF-PBMC, it can be calculated
that in CF cells calpain activity is at least 3–4 fold higher. Moreover,
while in C-PBMC the basal calpain activity reached values correspond-
ing to approximately 5% of the activity elicited by the Ca2+-ionophore
treatment, in untreated CF-PBMC it is close to half of the value mea-
sured in the presence of Ca2+-ionophore. These observations support
the hypothesis that, in cells carrying Phe508deleted CFTR, Ca2+homeo-
stasis is sufﬁciently altered to promote a constitutive activation of cal-
pain. This is consistent with the observation that calpain-mediated
CFTR digestion is highly accelerated in CF-PBMC [13]. The increase in
calpain activity observed in CF-PBMC exposed to Ca2+-ionophore
could be due to an overexpression of the protease or to a consumption
of the natural inhibitor of calpain. Thus, we havemeasured both protein
and activity of the two components of the proteolytic system. As shown
in Fig. 1C, calpain activity was poorly affected in CF cells, whereas cal-
pastatin was reduced to approximately 50% of controls, both as protein
and inhibitory activity. This observation indicates an unbalance in the
regulation of the Ca2+-dependent proteolysis in CF-PBMC and is in
agreement with the abnormal activation of calpain detectable in these
cells.
To establish if this alteration in Ca2+ homeostasis and calpain activ-
ity in CF-PBMC could affect other members of the functional complex
taking origin from CFTR at membranes [30,31], we have selectedNHERF-1 scaffolding protein, since it represents the molecular bridge
from proteins at the plasma membrane and other partners facing the
cytoplasm compartment. As shown in Fig. 2A, in PBMC from healthy
donors NHERF-1 was preferentially localized at the cell periphery. In
particular, by scanning the green ﬂuorescence of the confocal micro-
scope images, it was established that approximately half of the total
NHERF-1 was present at the cell periphery probably associated to
plasma membranes (Fig. 2C). On the contrary, in PBMC from patients
homozygous for F508del-CFTR, more than 95% of total NHERF-1 was
distributed into the cytoplasm. It is remarkable that in CF-PBMC the
alteration in NHERF-1 localization was qualitatively and quantitatively
similar to that of F508del-CFTR (Fig. 2B and D). In fact, while in con-
trol cells approximately 40% of total CFTR was associated to plasma
membranes and the remaining 60% was detected in endosome mem-
branes [14], in cells from CF patients less than 5% of this protein was
detectable on the plasma membranes, being almost all of the protein
conﬁned in a cytoplasmic localization. Thus, similar changes in cell
distribution occurring to both proteins suggested a close interaction
between CFTR and NHERF-1. Moreover, the absence of F508del-CFTR
at the plasma membranes further supported the activation of calpain
in CF-PBMC. To conﬁrm this assumption we have analyzed the molecu-
lar forms of both CFTR and NHERF-1 in control and CF-PBMC.
As shown in Fig. 2E in C-PBMC, CFTR was present in a native and in
a digested form. Using a mAb directed against the C-terminal of the
protein, in addition to the native 170 kD, a larger amount of the
100 kD form was also detected as already reported in [14]. When
we used a different antibody directed against the N-terminal region,
a second 70 kD band was observed, indicating that CFTR is cleaved
by calpain in two discrete fragments one of a 100 kD and the other
of 70 kD, the latter corresponding to the N-terminal portion of the
channel. Quantiﬁcation of the CFTR bands revealed that the mean
value of the ratios between the digested and native protein channel
forms was 4.6 when we used the C-terminal antibody and 4.2 when
we used the N-terminal antibody. Thus, the similarities in these
values indicate that calpain promotes the cleavage of one or few
Fig. 2. Localization and association of NHERF-1 and CFTR in PBMC from control and CF patients. PBMC (10×106) from control and CF patients were ﬁxed and permeabilized following the
Triton/paraformaldehydemethod [19]. (A)NHERF-1 localizationwas determined by confocalmicroscopy using anti-NHERF-1 antibody. (B) CFTR localizationwas determined by confocal
microscopy usingM3A7mAb (see Section 2.5). Representative images are shown in both panels. The green ﬂuorescence refers to the Ab stained protein and the red ﬂuorescence refers to
propidium iodide stained DNA (see Section 2.5). Fluorescence intensity wasmeasured and quantiﬁed by cell scanningwith Laser Pix Software as in [25]. Spectra of four cells from control
(straight line) and from CF patients (dashed line) are reported (C and D). (E) Aliquots (20 μg) of the total material (see Section 2.6), prepared from PBMC of control or CF patients were
solubilized in Laemmli SDS-PAGE loading solution, incubated at 37 °C for 30 min, and submitted to 6% SDS-PAGE followedby immunoblotting. CFTR formswere detectedusingM3A7mAb
(C-ter. Ab) or anti-CFTR polyclonal antibody (N-ter. Ab). (F) Alternatively, aliquots (20 μg) of the total material from control or CF-PBMC solubilized in Laemmli loading solution were
heated at 95 °C for 5 min and submitted to 12% SDS-PAGE followed by immunoblotting. The different NHERF-1 forms were detected using anti-NHERF-1 antibody. The blot images
shown are representative of four different experiments. (Lower panels) Total membrane fractions isolated from 10×106 control or CF PBMC were solubilized in 1% Triton® X-100 and
immunoprecipitation was carried out using anti-CFTR mAb M3A7 or, as control, using only protein G-Sepharose (see Section 2.7). NHERF-1 from immunoprecipitation carried out
with anti-CFTR mAb M3A7 (lanes 1) and NHERF-1 from immunoprecipitation with only protein G-Sepharose (lanes 2) were detected as in (E) and in (F).
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and the regulatory domain of CFTR. These data are in agreement with
previous observations indicating that calpain-generated CFTRfragments remained associated each other into the membrane moiety
[14]. Similar analyses carried out on PBMC from patients homozygous
for F508del-CFTR (Fig. 2F) showed that native 170 kD CFTR was
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and 70 kD fragments was still detectable in internal membranes.
Instead, NHERF-1 was detected in C-PBMC as a single form showing
a mass of 50 kD, whereas in CF-PBMC the anti NHERF-1 antibody
revealed, in addition to the native 50 kD form, the presence of a second
protein band showing amass of 20 kD. The interaction of NHERF-1with
native or split CFTRwas explored by immunoprecipitation experiments
(Fig. 2E and F, lower panels). Using an anti-CFTR antibody, it has been
established that NHERF-1 was associated to CFTR both in control and
CF patients. Since NHERF-1 was associated to CFTR also in CF-PBMC, in
which the channel was present almost exclusively in the split form, it
can be postulated that CFTR/NHERF-1 interaction occurs regardless of
mutation as well as digestion and localization of the protein.
Moreover the same experiments revealed also that both native
and 20 kD NHERF-1 forms were associated to the mutated CFTR
split form, thus providing an explanation for the presence of
NHERF-1 observed in cytoplasm of CF-PBMC and its absence in plas-
ma membranes, as indicated by the intense cytosolic ﬂuorescence.
The low amount of 20 kD NHERF-1 detected in the immunoprecipita-
tion experiments and shown in Fig. 2F could be due to a competition
for binding to the immobilized CFTR between the two NHERF-1
forms, present in different amounts.
3.1. NHERF-1 is an “in vitro” calpain substrate
To demonstrate that the appearance of the 20 kD NHERF-1 form
could be the result of a limited proteolytic attack occurring on the na-
tive form, we have investigated the involvement of calpain by expos-
ing total membrane fractions from C-PBMC containing NHERF-1 to
puriﬁed calpain. As shown in Fig. 3A, the native 50 kD protein bandFig. 3. Effect of ezrin on NHERF-1 digestion by calpain in CFTR containing complex. Aliquot
Section 2.6, were incubated at 37 °C for 5 min in the presence of 1 unit of isolated human er
heating in Laemmli SDS-PAGE loading solution and the samples were submitted to 12% SDS
speciﬁc antibodies. The blot images shown are representative of three different experiments.
as in (A) in the presence of human erythrocyte calpain for 5, 10 and 20 min. NHERF-1 forms
(C) Schematic representation of the conformational changes occurring on NHERF-1 [31] and t
(20 μg) of total membrane fractions prepared from C-PBMC (D) were washed with 0.5 M Na
material) and the pellet (washed membranes) were separately collected and treated with cwas 60–70% reduced and replaced by two additional bands having
masses of 35 kD and 20 kD although showing different intensities.
None of these digestion fragments were produced in the presence of
C.I.1. A time course analysis (Fig. 3B) revealed that the rate of accu-
mulation of the two proteins was different. In fact, the level of
20 kD band was, following 20 min of incubation, at least ﬁve-six
fold higher than that of the 35 kD form. The formation of two differ-
ent products could be the result of a two steps proteolytic process
converting ﬁrst the 50 kD form in the 35 kD fragment and then in
the 20 kD form. Alternatively, the two products could be produced in-
dependently by a concomitant double attack of calpain. The two
cleavage sites could be recognized by calpain with a different afﬁnity,
which could also explain their different accumulation. The hypothesis
of the two cleavage sites was based on the fact that NHERF-1 can as-
sume two distinct conformations depending on the context in which
the protein is localized. In fact, it has been reported [31] that NHERF-1
could acquire a tight conformation when the two PDZ-binding do-
mains and the ERM-binding domain are free and can be converted
in a more relaxed form following association of ligands to such sites
(Fig. 3C). On the basis of the position of the antibody epitope on the
protein molecule, it can be established that calpain cleavage occurs
between the two PDZ domains, producing the 35 kD fragment, or be-
tween the second PDZ domain and the ezrin binding domain, gener-
ating the 20 kD fragment (Fig. 3C). To verify whether NHERF-1
conformation was involved in addressing calpain on one or on the
other cleavage site, NHERF-1 was removed from its association with
CFTR complexes by washing total membrane fraction with 0.5 M
NaCl in order to separate particulate from solubilized fractions. As
shown in Fig. 3D, following incubation with puriﬁed calpain, the sol-
ubilized NHERF-1 was exclusively converted into the 20 kD fragment,s (20 μg) of total membrane fractions (A), prepared from control PBMC as described in
ythrocyte calpain [16] and 1 mM CaCl2 . The reaction was stopped by solubilization and
-PAGE followed by immunoblotting. Ezrin and NHERF-1 forms were detected using the
(B) Aliquots (20 μg) of total membrane fraction prepared from C-PBMC were incubated
were detected using the speciﬁc antibodies and quantiﬁed as described in Section 2.7.
he molecular organization of the NHERF-1 fragments generated by calpain. (D) Aliquots
Cl as described in Section 2.6 and following centrifugation the supernatant (solubilized
alpain (+ calp.) as in (A).
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into the 35 kD protein species, conﬁrming the presence in NHERF-1 of
two alternative calpain cleavage sites. The formation of the 35 kD
fragment was observed only when ezrin was present in high amounts
in the incubation mixture suggesting that the conformational change
induced by association of NHERF-1 to ezrin [32], promoting an in-
crease in the binding capacity of PDZ-domains, was directly related
to the accessibility of calpain to the 35 kD generating cleavage site.
Conversely, in preparations lacking ezrin, calpain preferentially pro-
duced the 20 kD NHERF-1 form (Fig. 3D).
3.2. Degradation of NHERF-1 by calpain in C-PBMC
To demonstrate if these NHERF-1 products were produced in cells
following calpain activation, C-PBMC were loaded with Ca2+ by incu-
bation with Ca2+-ionophore A23187. As shown in Fig. 4A and B, in
concomitance with the almost complete conversion of the 170 kD
CFTR into the digested (100 kD+70 kD) form, a 35 kD NHERF-1 pro-
tein band was accumulated. Digestion of both proteins was prevented
by preloading C-PBMC with C.I.1 (data not shown). The high levels of
ezrin present in these cells could explain the absence of the 20 kD
(Fig. 4C). Thus, the association of NHERF-1 with its partner proteins
addresses calpain only to the low afﬁnity cleavage site generating
the 35 kD fragment. These proteolytic events are accompanied by a
redistribution of CFTR and NHERF-1, both becoming internalized
into the cytoplasm (Fig. 4D and E). Altogether these ﬁndings are
clearly indicating that CFTR functional cluster is target of calpain.
However, the most sensitive substrate of the protease is CFTR and
its limited proteolysis is required for the recycling of this protein in
cytoplasm. NHERF-1 is also a calpain substrate but its fragmentation
occur in conditions promoting a massive calpain activation as it oc-
curs during exposure of cells to Ca2+-ionophore or in CF-PBMC.
Thus the accumulation of the 20 or the 35 kD fragments is indicative
of a pathological condition mediated by calpain overactivation.Fig. 4. Effect of NHERF-1 and CFTR digestion on their distribution in Ca2+-loaded PBMC. (A) P
30 min at 37 °C in 10 mMHepes pH7.4, containing 0.14 MNaCl, 5 mMKCl, 5 mMGlucose and 2
SDS-PAGE loading solution, incubated at 37 °C for 30 min, and submitted to 6% SDS-PAGE follow
(20 μg) were solubilized in loading solution, heated at 95 °C for 5 min and submitted to 12% SD
speciﬁc antibodies. The blot images shown are representative of four different experiments. CFT
confocal microscopy using the speciﬁc antibodies (see Section 2.5). The images are representaHowever, the presence of the 20 kD fragment in CF cells is also indi-
cating that the accessibility of calpain protein target in CFTR function-
al complex is also altered.3.3. Correlation between the 20 kD NHERF-1 form and CF pathology
To establish if the presence of this scaffolding fragment is charac-
teristic of cells containing the mutated F508del-CFTR, PBMC from 12
CF patients homozygous for F508del-CFTR mutation were analyzed
together with PBMC from 10 healthy donors. As shown in Fig. 5A, na-
tive 50 kD NHERF-1 was present in cells from both control and CF pa-
tients. However, the mean values of NHERF-1 level in cells from CF
patients was 1.1–1.2 fold higher than in controls, probably due to a
higher expression of this scaffolding protein in CF-PBMC.
Instead, the 20 kD form was exclusively detected in cells from all
CF patients and absent in cells from all control subjects. The amount
of 20 kD NHERF-1 varied from 4 to 16% of total with an average
value corresponding to approximately 10%. Altogether these observa-
tions indicate that the presence of the 20 kD NHERF-1 form could be
considered typical for cells expressing the mutated F508del-CFTR.
This conclusion is supported by the ﬁnding that in PBMC of heterozy-
gous parents, the 20 kD NHERF-1 form is absent and the level of the
native form is very similar to control (Fig. 5A and B). Since the forma-
tion of the 20 kD fragment seems to require the disorganization of the
CFTR functional complex, we have analyzed the effect of Phe508 dele-
tion in CFTR on the association of NHERF-1 to membranes. As shown
in Fig. 6A, while in C-PBMC the 50 kD NHERF-1 form was equally dis-
tributed in both soluble and membrane fractions, in cells from CF pa-
tients the level of the soluble NHERF-1 protein was 1.5–1.6 fold
higher than in controls whereas, the particulated form was ﬁve fold
lower as compared to control cells (Pb0.0001). The 20 kD NHERF-1
protein, present exclusively in CF-PBMC was detected in both cell
fractions (Fig. 6B).BMC (10×106 cells) were treated with 2 μM Ca2+-ionophore A23187 (Ca2+-loaded) for
mMCaCl2. After treatment, aliquots (20 μg) of the incubationwere solubilized in Laemmli
ed by immunoblotting. CFTR formswere detectedusingM3A7mAb. Alternatively, aliquots
S-PAGE followed by immunoblotting. NHERF-1 (B) and ezrin (C) were detected using the
R andNHERF-1 localization (D and E) in control and Ca2+-loadedPBMCwas determinedby
tive of four different experiments.
Fig. 5. Levels of 50 kD and 20 kDNHERF-1 in PBMC from control and CF patients. Aliquots
(30 μg) of the totalmaterial (see Section 2.6), prepared fromPBMCof 10 controls (control)
or 12 CF patients (CF) or 3 heterozygous parents (Par.) were solubilized in Laemmli
loading solution, heated at 95 °C for 5 min and submitted to 12% SDS-PAGE followed
by immunoblotting. NHERF-1 forms were detected using anti-NHERF-1 antibody.
The immunoreactive bands, corresponding to molecular masses of 50 kD (A) and
20 kD (B), were quantiﬁed as described in Section 2.7. Statistical analysis with Anova
test for a single factor revealed that the 95% conﬁdence intervals of the three groups did
not superimpose showing a p-value≤0.0001.
Fig. 7. Level of ezrin in PBMC from control and CF patients. Aliquots (20 μg) of total
material prepared from PBMC of 4 controls (C), 4 CF patients (CF) and 3 heterozygous
parents (Par.) were solubilised, heated and submitted to 12% SDS-PAGE followed by
immunoblotting. Ezrin was detected using 18/Ezrin mAb and the immunoreactive
bands were quantiﬁed as described in Section 2.7.
1655M. Averna et al. / Biochimica et Biophysica Acta 1812 (2011) 1649–1657These ﬁndings indicate that the Phe508 deletion induces a lower
afﬁnity of CFTR for NHERF-1 resulting in disassembly of the complex
and explaining the higher susceptibility of NHERF-1 to calpain diges-
tion. The data shown in Fig. 6C and D demonstrate this assumption
because NHERF-1 can be washed out frommembranes only if the mu-
tated and split CFTR is accumulated.
Moreover, preliminary observations show that ezrin, a known cal-
pain substrate [33], is signiﬁcantly reduced in CF-PBMC (Fig. 7),Fig. 6. Level and distribution of NHERF-1 forms in PBMC from control and CF patients.
Aliquots (20 μg) of soluble and membrane fractions (see Section 2.6) prepared from
PBMC of 10 controls (Control) and 12 CF patients (CF)were solubilized in Laemmli load-
ing solution, heated at 95 °C for 5 min and submitted to 12% SDS-PAGE followed by im-
munoblotting. NHERF-1 forms were detected using anti-NHERF-1 antibody. The
immunoreactive bands, corresponding to the molecular masses of 50 kD (A) and
20 kD (B), were quantiﬁed as described in Section 2.7. Aliquots (20 μg) of membrane
and washed membrane fractions (see Section 2.6) prepared from PBMC of 4 controls
(C) and 4 CF patients (CF) were solubilised, heated and submitted to 12% SDS-PAGE
followed by immunoblotting. NHERF-1 forms were detected using anti-NHERF-1 anti-
body. The immunoreactive bands, corresponding to molecular masses of 50 kD and
20 kD, were quantiﬁed as described in Section 2.7 and the values are reported as the
arithmetic mean±S.D.further demonstrate the disorganization of the CFTR complex as in
this condition NHERF-1 assumes the conformation convertible by cal-
pain into the 20 kD fragment.4. Discussion
A number of transmembrane channel proteins display PDZ-binding
modules recognized by scaffolding proteins and operating as linkers be-
tween the channels and other proteins generating functional complexes
[6–9].
Thus, the scaffolding proteins assemble these complexes concen-
trating and positioning transporters and enzymes in close proximity
to their substrates or regulatory proteins, avoiding non speciﬁc inter-
actions and favouring signal transduction processes [1,2].
CFTR generates a speciﬁc functional protein complex through the
association to NHERF-1 protein which then recruits in addition to
other channels, cytoskeletal elements (ezrin, radixin, moesin) and
PKA, the regulator of the CFTR channel activity [10]. The functional re-
lationship between CFTR and NHERF-1 is further demonstrated by the
increase of F508del-CFTR in plasma membrane following overexpres-
sion of this scaffolding protein [34,35].
It has been reported that many transmembrane ion channels, such
as NMDAR, CFTR, AMPA, L-type Ca2+-channels and other components
of their complexes are substrate of calpain [11,12], which catalyzes a
conservative proteolysis usually resulting in functional changes of the
target protein [36]. We have observed that calpain could be inserted
into these protein clusters through the chaperone HSP90 that associ-
ates with the protease reducing its sensitivity for Ca2+ ions [37].
Through this interaction the protease is brought in close proximity
of its substrates [37]. Calpain digestion of these functional complexes
could be involved in the control of the transmembrane ion conduc-
tance. This is supported by the fact that calpain-mediated limited pro-
teolysis of CFTR occurs in growing cells as well as in circulating
lymphocytes and following digestion the channel is recycled into
the cytoplasm [14]. A similar process is also suggested to occur for
NMDA receptor [12].
On the basis of these ﬁndings we are now proposing a new phys-
iological role of calpain in controlling the level of ion channels at plas-
ma membrane and thereby the ion ﬂux across these structures.
Accordingly, it can be postulated that an abnormal intracellular cal-
pain activation could result in a massive increase in the degradation
rate of a speciﬁc ion channel, promoting an almost complete removal
of this protein from plasma membrane. In this condition calpain
changes from a physiological to a pathological role. Experimental ev-
idence in support of this calpain function has been obtained by ana-
lyzing PBMC of patients homozygous for the F508del-CFTR. We are
here reporting that calpain is abnormally active in CF-PBMC due to
an alteration in the protease regulatory mechanism probably
1656 M. Averna et al. / Biochimica et Biophysica Acta 1812 (2011) 1649–1657accompanied also by increase in [Ca2+]i[38]. In these conditions pro-
teolysis and internalization of the mutated CFTR are highly accelerat-
ed causing the absence of the channel from its functional localization
at the plasma membrane. We have also established for the ﬁrst time
that NHERF-1, a CFTR partner, is a substrate of calpain that recognizes
two sites differing for their afﬁnity for the protease. The accessibility
of these cleavage sites is dependent on the NHERF-1 conformation
which is affected by protein interaction at the PDZ and ERM domains.
Thus calpain can convert NHERF-1 into different products showing
masses of 20 and 35 kD. It is relevant the fact that in normal cells fol-
lowing calpain activation NHERF-1 digestion generates exclusively
the 35 kD digested form, whereas in CF cells, in which calpain is al-
ready active, only the 20 kD form is produced. Although the presence
of one or the other NHERF-1 fragment is indicative of an overactiva-
tion of calpain and of its pathological function, it remains to establish
why the 35 kD fragment is never detectable in CF patients cells. Our
observations are suggesting that this is the result of a reduced afﬁnity
of the mutated CFTR, regardless if it is split or not, for NHERF-1 caus-
ing a disorganization of the CFTR functional complex. In this altered
organization of the cluster calpain recognizes, in addition to its natu-
ral substrate CFTR, also NHERF-1 generating the 20 kD form as well as
ezrin. The susceptibility of these proteins to calpain proteolysis opens
a new ﬁeld of investigation on its possible involvement in cell trans-
formation since it has been suggested that NHERF-1 can act also as
a tumour suppressor [39–44].
Moreover, the pathological role of calpain in CF cells could be further
increased by the effect of its activation in cell pulmonary infections.
Indeed, a recent report indicates that calpain inhibition prevented
staphylococcal penetration through monolayers of airway epithelial
cells [45].
The transition from a physiological to a pathological calpain func-
tion can occur also in nervous cells mediated by the digestion of the
Ca2+-channels NMDA or AMPA receptors [11,46].
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